The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PREDICT1: An observational study for identifying blood biomarkers associated with clinical benefit from carboplatin and pemetrexed (CbP) treatment in patients with non-squamous (NS) non-small cell lung cancer (NSCLC) (CJLSG1201).
 
Tetsunari Hase
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Taiho Pharmaceutical (Inst)
 
Kiyoshi Yanagisawa
No Relationships to Disclose
 
Asuki Fukatsu
No Relationships to Disclose
 
Tomoki Kimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyorin; MSD; Novartis; Ono Pharmaceutical; Pfizer
 
Eiji Kojima
No Relationships to Disclose
 
Takashi Abe
No Relationships to Disclose
 
Kazuyoshi Imaizumi
Research Funding - Lilly (Inst); MSD K.K (Inst)
 
Yoshitsugu Horio
No Relationships to Disclose
 
Tetsuya Oguri
Research Funding - Boehringer Ingelheim
 
Masashi Yamamoto
No Relationships to Disclose
 
Tomohiko Ogasawara
No Relationships to Disclose
 
Yasuteru Sugino
No Relationships to Disclose
 
Masahiro Morise
Speakers' Bureau - Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Lilly
 
Masahiro Nakatochi
Research Funding - Boehringer Ingelheim (Inst)
 
Masahiko Ando
Consulting or Advisory Role - Asahi Kasei
Research Funding - Kyowa Hakko Kirin (Inst)
 
Masashi Kondo
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD K.K; Ono Pharmaceutical; pfizer
Consulting or Advisory Role - Novartis
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Hideo Saka
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyorin; MSD K.K; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst)
 
Hiroshi Saito
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Yoshinori Hasegawa
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD K.K; Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takashi Takahashi
No Relationships to Disclose